Overview

Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of a 4-week fludrocortisone (FLU) treatment on systolic blood pressure depression after 5 minutes of active orthostatism in patients with neurogenic orthostatic hypotension (HON) symptomatic, despite treatment with non-drug measures with or without midodrine.
Phase:
Phase 4
Details
Lead Sponsor:
H.A.C. PHARMA
Treatments:
Fludrocortisone